Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients
Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients
Recruiting · NCT06650332 · Registry updated 2024-10-21Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients | Metastatic HER2 Positive Gastroesophageal Junction Cancer | Recruiting | Phase 1 / Phase 2 | 2024-10-21 | NCT06650332 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Zhejiang Cancer Hospital | 142 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Zhejiang Cancer Hospital | Hangzhou | China | 164 |